ArticleFrontiers in cardiovascular medicine2025
Long-term outcomes according to absolute value vs. percentage reduction in low-density lipoprotein cholesterol levels after acute myocardial infarction.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association of Relative LDL-Cholesterol Reduction With Cardiovascular Outcomes After Percutaneous Coronary Intervention.Journal of atherosclerosis and thrombosis · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backgrounds/aims: Real-world data are limited regarding long-term outcomes in terms of absolute follow-up values of low-density lipoprotein cholesterol (LDL-C) vs. percentage reductions from baseline after LDL-C-lowering therapy for patients with acute coronary syndrome. We aimed to investigate the associations between 5-year clinical outcomes and absolute follow-up LDL-C levels or percentage reductions from baseline using a nationwide Korea Acute Myocardial Infarction Registry (KAMIR). Methods: Of 13,662 patients from the KAMIR-National Institutes of Health database, we identified 6,248 patients who had documented LDL-C levels at baseline and during 18 months of follow-up. The primary outcome was major adverse cardiovascular events (MACE; a composite of nonfatal stroke, nonfatal myocardial infarction, repeat revascularization, and all-cause death) at 5 years. Results: In the analysis of absolute follow-up time-weighted average LDL-C levels (<55, 55-69, 70-89, and ≥90 mg/dL), there was a U-shaped trend of MACE incidence (10.8% vs. 9.3% vs. 10.0% vs. 13.2%, Conclusion: This study involving 6,248 AMI patients demonstrated that the greater the LDL-C reduction from baseline, the lower the risk of MACE. However, there was no clear decreasing trend in the risk of MACE when absolute follow-up LDL-C levels were lowered from around 70 mg/dL.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.